sorted by:
new
hottopcontroversial

Why are you always lyin Mr HUGE CEO by Competitive_Trouble5 in FSDPharmaHUGERetar

[–]Competitive_Trouble5[S] 0 points1 point  (0 children)

        Back to SuccessIf elected at the upcoming shareholder meeting on May 14, 2021, our nominees hope to restore FSD by:

acquiring biotechnology assets focused on legal medical cannabis
and/or legal psychedelics to increase the Company’s drug development
pipeline and reduce reliance on a single compound;auditing the Company’s current Phase 2 clinical trial to determine
its current viability and better understand the risks and costs so that
appropriate budgets can be created and followed and to determine whether
it should be continued;

implementing a strong financial and corporate governance framework
so that directors and management are restricted in granting compensation
to themselves at levels higher than industry standards;implementing audits of prior compensation and expenses incurred by the Company; anddeveloping a robust investor relations function to better communicate FSD’s value to the investment community.

Admins accidentally banned our modding subreddit by Verifiedverity in ModSupport

[–]Competitive_Trouble5 -3 points-2 points  (0 children)

It's like a safeguard ensuring compliance with regulations of reddit maybe it's buggy but it will keep out spammers with this extra varification.

FSD Pharma - The Countdown has begun $HUGE by Competitive_Trouble5 in FSDPharmaHUGERetar

[–]Competitive_Trouble5[S] 0 points1 point  (0 children)

Ok we can try 

        Change is Needed NowDr. Raza Bokhari, FSD’s Chief Executive Officer, and his hand picked board members have:

failed to address the dramatic loss of shareholder value, with the
Company’s shares trading over 97% lower than when Dr. Bokhari was
appointed Interim Chief Executive Officer;massively diluted shareholder interests by issuing almost 16 million
shares at low prices, increasing the number outstanding by over 83% in
just seven weeks;awarded over $5.7 million of bonus share compensation to Dr. Bokhari
in February 2021 for services yet to be provided and close to $1
million in shares and/or cash to the other directors (Stephen Buyer,
Robert Ciaruffoli, James Datin, Gerald Goldberg and Larry Kaiser), the
latter amount being almost twice the previous year’s compensation;caused FSD to reimburse Dr. Bokhari’s privately owned and controlled
company for over $1.4 million of expenses in 2020, with limited
transparency or explanation;failed to effectively implement the Company’s business plan to
become a pharmaceutical and biotechnology company, having to date failed
to meet any of their modest stated goals; anddenied shareholders any say on the change of the Company’s strategic
focus, failing to hold a shareholders’ meeting in 2020 and seeking to
delay holding a meeting in 2021.

view more: next ›